More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Novartis Drops Presbyopia Candidate UNR844 After Disappointing Trial Results
Author: Joan McKenna
Swiss company Novartis reported Oct. 25 that it had dropped its program for presbyopia treatment candidate UNR844 after seeing disappointing interim results from its Phase IIb trial. In its Q3-2022 earnings report, Novartis said interim analysis of the dose ranging study in patients ages 45 to 55 with presbyopia did not demonstrate a statistically significant dose response at Month 3. In its earnings call, the company said it had taken an impairment charge related to UNR844 of roughly $500 mi...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.